An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.
Clinical trial NCT03084471 · COMPLETED
Trial details
- NCT number
- NCT03084471
- Sponsor
- AstraZeneca
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-05
- Primary completion
- 2020-03-31
- Enrollment
- 867
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.